Durham, NC, United States of America

Kate Anna Dwornik


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Kate Anna Dwornik

Introduction

Kate Anna Dwornik, an accomplished inventor based in Durham, NC, has made significant strides in therapeutic innovations. With a focus on developing novel compounds, her work aims to enhance the medical field, particularly in targeting specific health conditions.

Latest Patents

Kate is credited with one notable patent: "Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40." This invention pertains to novel therapeutic compounds, particularly their use as GPR40 agonists. The patent details the processes for their manufacture and highlights intermediates that are essential for their preparation, marking a vital advancement in pharmacological research.

Career Highlights

At GlaxoSmithKline LLC, Kate has been pivotal in pushing the boundaries of what's possible in drug development. Her contributions not only reflect her innovative spirit but also her commitment to improving health outcomes through her scientific endeavors.

Collaborations

In her professional journey, Kate has collaborated with esteemed colleagues, including David Francis Corbett and Dulce Maria Garrido. These partnerships have been instrumental in advancing her research and ensuring the successful production of her patented compounds.

Conclusion

Kate Anna Dwornik exemplifies what it means to be a leading inventor in the pharmaceutical industry. Her patent on GPR40 agonists is a testament to her innovative mindset and dedication to improving therapeutic options. As she continues to work with GlaxoSmithKline LLC and her esteemed colleagues, the medical community eagerly anticipates her future contributions to the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…